TrikenolAcne-prone skin treatment.

Bacterial proliferation inhibition,anti-irritant, sebum regulation and

keratolytic effects

Seboregulating

provitalgroup.com

Technical specifications

Trikenol 75800

PROPERTIES Inhibition of bacterial proliferation. Anti-irritant. Anti-seborrhea. Keratolytic. Comedolytic

ACTIVE MOLECULES TriketonesSalicylic derivatives

APPEARANCE LiquidColor: yellow - dark yellow

SOLUBILITY Soluble in surfactants mixture and in hydroalcoholic solutions

RECOMMENDED 0.20 % Oily skinDOSE 0.80 % Acne-prone skin

Formulation

Oily skin tonic

A

B

C

D

% (w/w)

78.8010.002.003.00

0.80

0.40

5.00

INCI / PCPC

Aqua (Water)Alcohol Denat.GlycerinPropylene Glycol

TRIKENOL

PPG-26-Butheth-26, PEG-40Hydrogenated Castor Oil

Hamamelis extract

Trikenol

Synergic complex containing Manukaconcentrate and Willow extract. Thisproduct is designed for acne proneskin treatment; it reduces sebumproduction, irritation and acts as acomedolytic.

Trikenol is a synergic blenddesigned as an activecompound that improves thehealth of oily, acne-prone skin.

Treatment of oily, acne-proneskin requires concomitantreduction of the involvedmicrobial flora, sebumproduction and irritation, andnormalization of thedesquamation process in thestratum corneum.

Features and benefits

In Vitro

Inhibition of bacterial proliferationStudy of activity against Propionibacterium acnes andStaphylococcus aureus.

Propionibacterium acnes Staphylococcus aureus

MIC SI

0.195% 0.097%

MIC SI

0.78% 0.195%

* SI= Strong Inhibition (a concentration that sufficiently reduces bacterialpopulation).

Trikenol is a bactericide and fungicide active ingredient,useful to treat oily, acne-prone skin.

Assay on primary culture of human keratinocytes.

* SA=Acetyl Salicylic Acid as the positive control.

Willow extract inhibits cyclooxygenase by 43.45%.

0

10

20

30

40

50

60

43.45

70

49.89

63.96

Willowextract0.1%

SA 0.1mM SA 1mM

Anti-irritant activity

Toxicological information

This product has been evaluated according to theavailable toxicological information, based on safetyassays and bibliographical data. These data allowthe conclusion that using this ingredient, under thenormal conditions for the use of cosmetics and atthe recommended concentrations, is free of risks.

Willow

Manuka

In Vivo

Method28 volunteers; daily application of a gel containing 0.8%Trikenol vs placebo; measurements after28 and 56 days.

1. Evaluation of toleranceA dermatologist classified Trikenol as well tolerated bythe skin.

3. Sebum-regulatory effect

Reduction in the amount of sebum (expressed as %) after 28 and 56days of treatment.

4. Self-evaluation of the cosmeticproperties and perceived efficacyTrikenol: good skin tolerability and positive evaluation ofits cosmetic properties by the volunteers.

TrikenolPlacebo

Sebum regulation

Healthier No sheen

Smooth and soft Moisturizing

Cosmetic self evaluation

Sebum index (S) TRIKENOL

Results T28 -9.0

Results T56 -30.3

18.6 -27.6

2.5 -32.8

Placebo Difference

Cosmetic applications

Acne prone skin treatment:

Lotions tonics and emulsions

Reduces the numberof blackheads, thus enhancingthe skin appearance

0

20

40

60

80

100

100%Comedolytic

response

Trikenol Placebo

% Comedolytic response

-25

-20

-15

-10

% -5

0

12.33

Trikenol (T) Placebo (P) Difference (T-P)

5

10

15

-9.35

-21.68

Average variation of the nº of blackheads (%)

2. Evaluation of the comedolyticresponse